about
Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptorsE-type prostanoid receptor 4 (EP4) in disease and therapySequential induction of prostaglandin E and D synthases in inflammation11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophilsThe role of the prostaglandin D2 receptor, DP, in eosinophil traffickingOn the mechanism of interaction of potent surmountable and insurmountable antagonists with the prostaglandin D2 receptor CRTH2Disturbance of peristalsis in the guinea-pig isolated small intestine by indomethacin, but not cyclo-oxygenase isoform-selective inhibitorsPGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2On the role of 25-hydroxycholesterol synthesis by glioblastoma cell lines. Implications for chemotactic monocyte recruitment.Basophil responses to chemokines are regulated by both sequential and cooperative receptor signaling.Inconsistent results of diagnostic tools hamper the differentiation between bee and vespid venom allergyOpposing roles of prostaglandin D2 receptors in ulcerative colitisAcyl chain-dependent effect of lysophosphatidylcholine on endothelial prostacyclin productionThe myeloperoxidase product hypochlorous acid generates irreversible high-density lipoprotein receptor inhibitorsAnti-psoriatic therapy recovers high-density lipoprotein composition and function.O-1602, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms.A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function.Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation.A biased non-Gαi OXE-R antagonist demonstrates that Gαi protein subunit is not directly involved in neutrophil, eosinophil, and monocyte activation by 5-oxo-ETE.Endothelial lipase (EL) and EL-generated lysophosphatidylcholines promote IL-8 expression in endothelial cells.Myeloperoxidase-derived oxidants induce blood-brain barrier dysfunction in vitro and in vivo.Double-stranded RNA attenuates the barrier function of human pulmonary artery endothelial cells.Aging affects high-density lipoprotein composition and function.A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils.Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signallingDilatation by angiotensin II of the rat femoral arterial bed in vivo via pressure/flow-induced release of nitric oxide and prostaglandinsStimulant action of pituitary adenylate cyclase-activating peptide on normal and drug-compromised peristalsis in the guinea-pig intestine.Different receptors mediating the inhibitory action of exogenous ATP and endogenously released purines on guinea-pig intestinal peristalsisInvolvement of mu- and kappa-, but not delta-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine.Differential peristaltic motor effects of prostanoid (DP, EP, IP, TP) and leukotriene receptor agonists in the guinea-pig isolated small intestineGPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils.Loss of intestinal GATA4 prevents diet-induced obesity and promotes insulin sensitivity in mice.Uremia alters HDL composition and functionEP4 receptor stimulation down-regulates human eosinophil function.Impaired Rho GTPase activation abrogates cell polarization and migration in macrophages with defective lipolysis.Cyanate is a novel inducer of endothelial icam-1 expression.Mediation by CCKB receptors of the CCK-evoked hyperaemia in rat gastric mucosa.Dialysis Modalities and HDL Composition and FunctionHigh-Density Lipoprotein Function in Exudative Age-Related Macular DegenerationPlasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo.
P50
Q24306707-CE0B02A2-8374-4980-A350-D1A1DE09D6C8Q26851156-D40CDDAB-A6EC-4391-AD58-481E441DD2B3Q28186256-B5B13EEA-BDE9-4E50-B3F2-7801216132A6Q28190702-AC03D240-6C09-4371-9BD9-BFCE43C035DBQ28249405-D4C15F07-BC10-40F8-AC06-9F23C4A2E499Q28292274-C28EB6CF-AAD1-436D-BA83-054A7F45EA59Q28360204-E8F2C8FE-2F18-4656-B554-5C754BD790AFQ28731227-161F3075-01BB-4640-B07A-E5CA39DC57CAQ33737051-116F4F46-6BC7-4305-A326-C0CD9572F5E2Q33928445-B5DBA32B-3194-4DD0-9C88-DEEF9A50CED4Q33941113-FEC2F997-6BCE-45C8-9310-E1900457578BQ34001819-FA571512-6A9B-4269-9062-C3F1D0201595Q34116412-23441343-268C-4B4F-9B97-2A0EA10D201CQ34178582-049D0A54-633F-4717-96A0-4160D35A1433Q34259215-AB85AC5D-B17F-41E3-BD25-1D415F08629EQ34298903-E423B024-AE73-414B-8173-583437033438Q34342626-55C39AE2-79EF-49BA-8479-92AA41B8579EQ34368772-4F01C23F-1120-427A-97F5-BEDED877388FQ34415252-E93DD372-EE79-432F-953B-7AA4B36CD7CDQ34553611-A2978DB3-3A7A-4C7B-BD93-F3A9075D4FD9Q34731236-48E5D57D-B555-4B94-8966-4FF64E2E01C2Q34765604-1EB69167-DCCB-4F51-AF05-4D55CE81CF9CQ34781392-BE2E21E2-B55C-4933-9175-F0DF8F077EAAQ34846451-1F04AB69-5A92-409B-B091-51E1533B68ECQ34953430-C27325CD-590D-40E8-955A-4819A6CEEFE7Q35026834-72189CA7-7E2C-439B-A793-55895F4BA759Q35028957-CEFCD5CE-8F77-4C3B-A441-B63A0F2DB13AQ35041540-4AD0007C-DCAF-44A4-BE63-5242C98108FCQ35044112-9E85B309-99B4-4078-A431-4548B73FA8D1Q35044758-DF248B29-5CA8-46E4-BD69-ECE3EC1CADD7Q35094180-457D56CC-BAAF-4D11-BB61-E054EBD8167BQ35185218-D3350230-D503-42C0-8DB8-C0EFF2E1D5DEQ35210194-6178BCEA-8C57-4274-BEF0-60D48D5D3AB5Q35332774-5585088F-7570-4A0F-9470-1347680BCBFBQ35544507-165975BD-BBE1-41BB-A27A-D63614C77C0CQ35567375-D8A86FBF-5A37-40FB-A8BA-B3F819B62B6DQ35872825-50485F69-2D32-422C-ACA7-059B84AB0FB5Q36003077-6F5ADC14-5CA7-44B3-8E15-C80D575EFA09Q36015473-F267B5F5-4999-4BDD-80B4-60EC052DDE37Q36032978-F7B4BE44-01FE-43FA-A6FE-7427543B1A54
P50
description
hulumtues
@sq
investigador
@pt
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Akos Heinemann
@ast
Akos Heinemann
@en
Akos Heinemann
@es
Akos Heinemann
@nl
Akos Heinemann
@pt
type
label
Akos Heinemann
@ast
Akos Heinemann
@en
Akos Heinemann
@es
Akos Heinemann
@nl
Akos Heinemann
@pt
prefLabel
Akos Heinemann
@ast
Akos Heinemann
@en
Akos Heinemann
@es
Akos Heinemann
@nl
Akos Heinemann
@pt
P106
P2038
Akos_Heinemann
P21
P31
P496
0000-0002-8554-2372
P569
2000-01-01T00:00:00Z